Drug Induced Hemolytic Anemia Treatment | Medical Algorithm

Are you evaluating a patient who has received chemotherapy?

Yes

Does the patient have?

• microangiopathic hemolytic anemia?

Yes

• thrombocytopenia?

Yes

• renal failure?

Yes

Were symptoms precipitated or worsened by red blood cell transfusion?

Yes

Has the patient received a high cumulative chemotherapeutic dose?

Yes

Have you excluded other causes of micro-angiopathic hemolytic anemia?

Yes

Chemotherapeutic agents given

Mitomycin C

Bleomycin

Cisplatin

Gemcitabine

Interferon

Other

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Does the patient have the hemolytic uremic syndrome?

Number of chemotherapeutic agents associated with HUS received by the patient

Number of features present that are seen in chemotherapy-related HUS

Could the patient have HUS caused by a chemotherapeutic agent?

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
Severity, Prognosis, Stage
- Score for Bleeding Following Bone Marrow Transplantation
- Scale for Bleeding Following Therapy for Acute Leukemia
Complications
- Score for Bleeding Following Bone Marrow Transplantation

Monitoring

Response To Therapy
- Scale for Bleeding Following Therapy for Acute Leukemia
Adverse Effects
Complication Detection
- Risk Score of Dranitsaris et al for Predicting Chemotherapy-Induced Anemia in a Woman with for Breast Cancer

Evaluation

Results

Please fill out required fields.

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Monitoring

Specialty

Objective

ICD-10

Hemolytic Uremic Syndrome Secondary to Chemotherapy

Purpose: To determine if a patient has developed a hemolytic uremic syndrome (HUS) secondary to chemotherapy.

Evaluation

Results

Please fill out required fields.

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Monitoring

Specialty

Objective

ICD-10